New hope for rare skin cancer: drug combo trial launches
NCT ID NCT06673628
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of two drugs, pembrolizumab and lenvatinib, in 38 people with a rare and aggressive skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if this treatment can shrink tumors and improve outcomes. Participants will receive the drugs for up to two years, with regular monitoring for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and lenvatinib
What this could lead to
If it works, this could offer a new treatment option for a rare skin cancer that currently has a very low survival rate.
What could go wrong
This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The combination may cause side effects and may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA OF SKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Faculty of Medicine, University of Miyazaki Hospital
RECRUITINGMiyazaki, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Keio University Hospital
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nagoya City University Hospital
RECRUITINGNagoya, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Kyoto Prefectural University of Medicine
RECRUITINGKyoto, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••